Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 1.21TCr 1.05TCr 990.22Cr 896.48Cr 1.68TCr 1,16000Cr 1.7TCr 12TCr 4.55TCr 59TCr 4.54TCr 4.44TCr 1,87500Cr P/E 2026 *
-82.9x
P/E 2027 * 83.1x
Enterprise Value 1.16TCr 1TCr 947.26Cr 857.59Cr 1.61TCr 1,10900Cr 1.62TCr 11TCr 4.35TCr 56TCr 4.34TCr 4.25TCr 1,79400Cr EV / Sales 2026 *
7.58x
EV / Sales 2027 * 5.2x
Free-Float
94.12%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.25TCr
-1.38%+0.20%+46.42%+96.33% 7.02TCr
-1.04%-0.81%+34.61%+75.16% 6.26TCr
-4.29%-3.98%-16.22%+350.66% 2.74TCr
+2.19%+2.99%+29.77%+15.37% 2.57TCr
-2.20%-2.00%-1.22%-14.48% 2.48TCr
+1.61%-0.69%+20.85%-19.42% 1.95TCr
+1.26%-14.23%+170.04%+298.75% 1.55TCr
-5.54%+0.69%-8.13%+830.48% 1.47TCr
-0.48%-4.32%-9.94%+454.46% 1.47TCr
Average -0.99%-2.20%+29.58%+231.92% 3.06TCr
Weighted average by Cap. -1.10%-1.32%+30.88%+160.72%

Financials

2026 *2027 *
Net sales 152.63Cr 132.21Cr 125.02Cr 113.18Cr 212.42Cr 15TCr 214.02Cr 1.49TCr 573.96Cr 7.42TCr 573.32Cr 560.61Cr 24TCr 214.49Cr 185.79Cr 175.68Cr 159.05Cr 298.51Cr 21TCr 300.76Cr 2.1TCr 806.58Cr 10TCr 805.68Cr 787.82Cr 33TCr
Net income -18Cr -16Cr -15Cr -14Cr -26Cr -1.76TCr -26Cr -179.72Cr -69Cr -894.31Cr -69Cr -68Cr -2.85TCr 20Cr 17Cr 16Cr 15Cr 28Cr 1.92TCr 28Cr 195.48Cr 75Cr 972.76Cr 75Cr 73Cr 3.1TCr
Net Debt -52Cr -45Cr -43Cr -39Cr -73Cr -5.03TCr -74Cr -512.69Cr -197.25Cr -2.55TCr -197.03Cr -192.66Cr -8.14TCr -94Cr -82Cr -77Cr -70Cr -131.27Cr -9.05TCr -132.26Cr -921.95Cr -354.7Cr -4.59TCr -354.3Cr -346.44Cr -15TCr
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
523.26USD
Average target price
678.06USD
Spread / Average Target
+29.58%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!